MUC1‑C Targeting with XYA02‑8‑ADC, for Castration‑Resistant and Neuroendocrine Prostate Cancer

/in , /by

In advanced prostate cancer, castration‑resistant and neuroendocrine variants present some of the toughest clinical challenges because they often lose dependence on androgen receptor signaling and become refractory to hormone‑targeted therapies. Within this resistant landscape, MUC1‑C, the C‑terminal subunit of the mucin‑1 oncoprotein, emerges as a promising alternative target. MUC1‑C is aberrantly overexpressed and under‑glycosylated in […]

Read more

JZY‑2233: A PSMA‑Targeted Degrader‑Antibody Conjugate for Advanced Prostate Cancer

/in , /by

Researchers have developed a new targeted therapy for advanced prostate cancer called JZY‑2233, a degrader‑antibody conjugate that homes in on prostate‑specific membrane antigen (PSMA) while delivering a highly potent CBP/p300 degrader directly to tumor cells. CBP and p300 are transcriptional coactivators that help the androgen receptor drive oncogenic gene programs in prostate cancer, and small‑molecule […]

Read more

NEOK001: A New Bispecific Antibody–Drug Conjugate for Advanced Prostate Cancer

/in , /by

A promising new experimental drug called NEOK001 (also known as ABL206) is emerging as a potential therapy for advanced cancers that express two specific proteins on their surface: B7‑H3 and ROR1. Among these cancers, prostate cancer is one of the tumor types where early data already show signs of activity, making NEOK001 a candidate of […]

Read more

Healthy Eating After Prostate Cancer Tied to Lower Risk of Frailty

/in /by

Eating a healthier diet after a prostate cancer diagnosis may help men age with more strength and resilience, according to a large prospective observational U.S. study that will be presented at the AACR 2026 meeting. The analysis followed more than five thousand men from the Health Professionals Follow‑up Study who were not frail when they […]

Read more

Higher Vitamin D Levels Before Diagnosis Linked to Better Prostate Cancer Survival

/in /by

A large international pooled analysis of over twelve thousand men with prostate cancer adds substantial evidence that men who have higher circulating levels of vitamin D before their diagnosis tend to live longer after developing the disease. The study, which will be presented at AACR Annual Meeting 2026, focused on 25‑hydroxyvitamin D, the major blood […]

Read more

JMKX007129: A Next‑Generation AR‑NTD Inhibitor for Overcoming Resistance in mCRPC

/in /by

JMKX007129 is a new small‑molecule drug that targets the N‑terminal domain (NTD) of the androgen receptor (AR) in prostate cancer. It is designed to overcome resistance seen with current AR‑ligand binding domain (LBD) inhibitors, which often stop working in castration‑resistant prostate cancer (CRPC) when AR develops mutations or produces splice variants like AR‑V7. JMKX007129 builds […]

Read more

AUTOTAC Degraders ATB‑238 and ATB‑239 Target AR and AR‑v7 in Advanced Prostate Cancer

/in /by

AUTOTACs (Autophagy‑Targeting Chimeras), are molecules designed to force cancer cells to “clean up” and destroy the androgen receptor (AR), a key driver of prostate cancer growth and progression. The latest research on two second‑generation AR‑targeting AUTOTACs, ATB‑238 and ATB‑239, shows that these compounds can effectively degrade not only the normal AR but also its troublesome […]

Read more

²²⁵Ac‑RAX104: A Next‑Generation PSMA Alpha Radioligand for Advanced Prostate Cancer

/in /by

RAX104 is a small molecule ligand designed specifically to target PSMA, the protein that is highly expressed on the surface of prostate cancer cells. When labeled with ²²⁵Ac, it forms a radioligand that combines the physical advantages of actinium‑225 (high linear energy transfer and a 10‑day half‑life) with a ligand engineered for better tumor retention. […]

Read more